Skip to main content

GILD Gilead Sciences, Inc.

Healthcare

170.68 Close 10/30
Since 2024-12-02 +91.6%
Open
170.25
High
175.65
Low
169.00
Prev close
165.61
Volume
11.3M
Amplitude
4.02%
P/B
16.2
Revenue YoY (TTM)
+6.5%
52W 114.02 175.65

Is Gilead Sciences, Inc. a buy? Fundamentals and valuation first

As of 2026-10-30

Momentum: Strong, Risk / liquidity: Strong; Valuation: Pricey, Growth: Weak.

Valuation Pricey Free-cash-flow yield is Good, but Price / book is Expensive.
TTM P/E -54.01 N/A
Price / book 16.24 95th percentile Expensive
Free-cash-flow yield (%) 6.63 73th percentile Good
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Neutral FCF margin, TTM is Top, but ROE, TTM is Average.
ROE, TTM (%) -29.63 22th percentile Average
Operating margin, TTM (%) -4.38 31th percentile Average
FCF margin, TTM (%) 45.3 91th percentile Top
Quality Factor Investing: A US Quality Value Backtest
Growth Weak Revenue growth, TTM YoY is Good, but Diluted EPS growth, TTM YoY is Lagging.
Revenue growth, TTM YoY (%) 6.54 52th percentile Good
Diluted EPS growth, TTM YoY (%) -148.99 13th percentile Lagging
Momentum Strong All 2 indicators are Top.
60-day return (%) 31.16 95th percentile Top
240-day return (%) 39.89 83th percentile Top
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Strong 20-day dollar volume is Top; 60-day annualized volatility is Good.
20-day dollar volume 948,219,562 99th percentile Top
60-day annualized volatility (%) 25.87 29th percentile Good
Factor Investing Explained: 10 Classic Factors in US Stocks

Gilead Sciences, Inc. (GILD) today

3 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From Gilead Sciences, Inc. to every stock like it

AI finds several complementary traits of Gilead Sciences, Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Gilead Sciences, Inc.

Gilead Sciences, Inc. (GILD) peers and tracking

Watchlist

This page refreshes daily after the close. Add Gilead Sciences, Inc. to your watchlist to track signal changes on your next visit.

Gilead Sciences, Inc. (GILD) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

15 historical occurrences (since 2017-08-30)

Average forward return after 52-week adjusted-price high

20-day: Win 57.1%, Sample 14, Median +1.02%, Excess +2.76%, Beat mkt rate 42.9%

60-day: Win 57.1%, Sample 14, Median +4.03%, Excess -0.04%, Beat mkt rate 50%

120-day: Win 64.3%, Sample 14, Median +4.52%, Excess -2.31%, Beat mkt rate 35.7%

120 days after: historical avg +2.93%

20-day +2.63%
60-day +1.01%
120-day +2.93%
20-day
60-day
120-day
Win
57.1%
57.1%
64.3%
Sample
14
14
14
Median
+1.02%
+4.03%
+4.52%
Excess
+2.76%
-0.04%
-2.31%
Beat mkt rate
42.9%
50%
35.7%

Over 14 occurrences, 120-day forward avg gained 2.93%, lagged the market by 2.31 pts; win rate 64.3%.

Top-quintile 6-month momentum

Active · now 84.3%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest
11 historical occurrences (since 2017-08-31)

Average forward return after Top-quintile 6-month momentum

20-day: Win 50%, Sample 10, Median +0.76%, Excess +3.49%, Beat mkt rate 60%

60-day: Win 50%, Sample 10, Median +1.73%, Excess -1.68%, Beat mkt rate 40%

120-day: Win 60%, Sample 10, Median +6.69%, Excess -1.27%, Beat mkt rate 40%

120 days after: historical avg +7.56%

20-day +1.96%
60-day +1.93%
120-day +7.56%
20-day
60-day
120-day
Win
50%
50%
60%
Sample
10
10
10
Median
+0.76%
+1.73%
+6.69%
Excess
+3.49%
-1.68%
-1.27%
Beat mkt rate
60%
40%
40%

Over 10 occurrences, 120-day forward avg gained 7.56%, lagged the market by 1.27 pts; win rate 60%.

EPS surprise beat

Active · now 16.44%

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest
27 historical occurrences (since 2015-02-03)

Average forward return after EPS surprise beat

20-day: Win 54.5%, Sample 22, Median +1.35%, Excess +1.54%, Beat mkt rate 54.5%

60-day: Win 72.7%, Sample 22, Median +4.08%, Excess +2.72%, Beat mkt rate 68.2%

120-day: Win 61.9%, Sample 21, Median +8.17%, Excess -0.94%, Beat mkt rate 47.6%

120 days after: historical avg +5.91%

20-day +2.11%
60-day +6.37%
120-day +5.91%
20-day
60-day
120-day
Win
54.5%
72.7%
61.9%
Sample
22
22
21
Median
+1.35%
+4.08%
+8.17%
Excess
+1.54%
+2.72%
-0.94%
Beat mkt rate
54.5%
68.2%
47.6%

Over 21 occurrences, 120-day forward avg gained 5.91%, lagged the market by 0.94 pts; win rate 61.9%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.